Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > talabostat

Talabostat : Point Therapeutics : DPP inhibitor

Clinical Development - Talabostat in Lung Cancer (Point Therapeutics)
Describes results of a phase II trial of talabostat in patients with advanced lung cancer. A phase III trial is planned.

Tarceva - Clinical Trials (


Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor